What is CJC‑1295 (No DAC) + Ipamorelin?
CJC‑1295 (No DAC) is an analog of growth hormone‑releasing hormone (GHRH) designed without the albumin-binding DAC segment, resulting in a short half‑life and preserving natural GH pulsatility. Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release without affecting other hormonal axes. When combined, these peptides may synergistically enhance pulsatile growth hormone secretion for use in metabolic and regenerative research models [1][2].
- CJC‑1295 (No DAC): A truncated GHRH analog that retains GH‑releasing capability but decays in approximately 30 minutes, preserving natural GH pulses [1].
- Ipamorelin: A synthetic pentapeptide (Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂) that selectively activates the ghrelin receptor (GHS-R1a), triggering rapid GH release without elevation of cortisol or prolactin—distinct from other GH secretagogues [3].
Structure
- CJC‑1295 (No DAC): Modified sermorelin‑like peptide lacking DAC, enabling a short half-life of ~30 minutes [1].
- Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂; molecular weight ~717 Da; selective ghrelin receptor agonist [3].
Research Highlights
- Tissue Repair and MetabolismElevated GH/IGF‑1 levels from this peptide combination are associated with increased protein synthesis, improved body composition, and enhanced recovery—though direct studies on the combined use remain preliminary [1][2].
- Safety ProfileIn clinical trials, CJC‑1295 (No DAC) was well-tolerated with no serious side effects, and Ipamorelin exhibited excellent specificity for GH release without activating other endocrine axes [1][3].
- Natural Pulsatility PreservationUnlike long-acting DAC versions, CJC‑1295 (No DAC) maintains the natural pulsatility of GH, which is crucial for physiological hormone signaling and downstream effects [1].
Reconstitution and dosing
CJC / Ipamorelin is typically reconstituted with Bacteriostatic water at 5 to 10mg per ml. Standard dosing is 100mcg twice per day up to 300mcg once to three times per day. Research demonstrates that CJC / Ipamorelin has a saturation dose of 1mg/kg, making 100mcg a standard dosing protocol, however some users report improved benefits up to 300mcg per administration. CJC / Ipamorelin is typically used for 6 months followed by a 2-3 month break. Some users prefer a strategy of utilizing CJC / Ipamorelin for 8 weeks followed by 8 weeks of a different Growth Hormone peptide, such a Tesamorelin.
For our free Peptide Calculator CLICK HERE
Disclaimer
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
Referenced Citations
- Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC‑1295, a long‑acting analog of GH‑releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799–805. Available at: https://pubmed.ncbi.nlm.nih.gov/16352683/
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. “Prospective, randomized, controlled, proof‑of‑concept study of the ghrelin‑receptor agonist ipamorelin for the management of postoperative ileus in bowel resection patients.” Int J Colorectal Dis. 2014;29(12):1527–1530. Available at: https://pubmed.ncbi.nlm.nih.gov/25331030/
- Smith RG, et al. “Ipamorelin, the first selective growth hormone secretagogue.” [PubMed PMID: 9849822]. Available at: https://pubmed.ncbi.nlm.nih.gov/9849822/
